SOAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Therefore, although JAK inhibitors (JAKis) constitute a new therapeutic option for the treatment of PTCL patients [20,26], further studies are needed to elucidate the relation between mutations and the activation of the JAK/STAT pathway as well as the mechanisms of JAKi resistance.